Inspire Pharmaceuticals has launched another trial of its proposed dry-eye drug known as diquafosol.

The trial comes after the FDA sent an approvable letter to Inspire in January but indicated that an additional clinical study was required.

Some 500 people at 36 sites in the United States will participate.

“We recently incorporated the final comments from the FDA into the protocol for this study and have begun patient enrollment,” said Christy Shaffer, CEO of Inspire. “We expect to report results and, if possible, submit an amendment to the (new drug application) by mid-2005.”

The trial calls for a double-masked placebo-controlled safety format. Diquafosol will be administered four times a day to those selected to get the drug rather than a placebo over a six-week period.